Barclays PLC Makes New Investment in Clover Health Investments, Corp. (NASDAQ:CLOV)

Barclays PLC acquired a new position in shares of Clover Health Investments, Corp. (NASDAQ:CLOV) in the 3rd quarter, Holdings Channel reports. The fund acquired 105,766 shares of the company’s stock, valued at approximately $298,000.

Other large investors have also modified their holdings of the company. Geode Capital Management LLC raised its stake in Clover Health Investments by 21.9% during the 3rd quarter. Geode Capital Management LLC now owns 4,828,701 shares of the company’s stock worth $13,622,000 after acquiring an additional 868,501 shares in the last quarter. State Street Corp grew its holdings in shares of Clover Health Investments by 65.0% during the third quarter. State Street Corp now owns 2,189,380 shares of the company’s stock worth $6,174,000 after purchasing an additional 862,621 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Clover Health Investments during the third quarter worth about $735,000. Parallax Volatility Advisers L.P. purchased a new stake in shares of Clover Health Investments in the 3rd quarter valued at about $38,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of Clover Health Investments in the 3rd quarter valued at about $477,000. Institutional investors and hedge funds own 19.77% of the company’s stock.

Clover Health Investments Stock Performance

NASDAQ CLOV opened at $4.08 on Tuesday. Clover Health Investments, Corp. has a one year low of $0.61 and a one year high of $4.71. The firm has a market cap of $2.04 billion, a PE ratio of -20.40 and a beta of 1.95. The firm’s fifty day moving average is $3.36 and its two-hundred day moving average is $3.02.

Clover Health Investments (NASDAQ:CLOV) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. The firm had revenue of $330.99 million for the quarter, compared to analysts’ expectations of $347.60 million. Clover Health Investments had a negative return on equity of 25.46% and a negative net margin of 5.92%. During the same quarter in the previous year, the firm posted ($0.09) EPS. Research analysts predict that Clover Health Investments, Corp. will post -0.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

CLOV has been the topic of several research analyst reports. Craig Hallum started coverage on Clover Health Investments in a research report on Tuesday, December 17th. They set a “buy” rating and a $6.00 price target on the stock. UBS Group assumed coverage on shares of Clover Health Investments in a research report on Monday, October 7th. They set a “neutral” rating and a $4.00 target price on the stock.

Clover Health Investments Company Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.